Moderna Inc (OQ:MRNA)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 200 Technology Sq
Cambridge MA 02139-3578
Tel: N/A
Website: https://www.modernatx.com
IR: See website
<
Key People
Noubar B. Afeyan
Non-Executive Independent Chairman of the Board, Co-Founder
Tal Zvi Zaks
Chief Medical Officer
Stephen Hoge
President
Stephane Bancel
Chief Executive Officer, Director
David W. Meline
Chief Financial Officer
Tracey Franklin
Chief Human Resource Officer
Juan Andres
Chief Technical Operations and Quality Officer
Lori Henderson
General Counsel, Company Secretary
Marcello Damiani
Chief Digital and Operational Excellence Officer
Ray Jordan
Chief Corporate Affairs Officer
   
Business Overview
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
Financial Overview
For the nine months ended 30 September 2020, ModernaInc revenues increased from $46.2M to $232.7M. Net lossincreased 21% to $474.6M. Revenues reflect Grant revenueincrease from $8.7M to $187.5M, Collaboration Arrangementincrease of 33% to $43.8M. Higher net loss reflectsResearch and development increase of 67% to $570.7M(expense), General and administrative increase of 39% to$82.5M (expense).
Employees: 830 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $53,419M as of Sep 30, 2020
Annual revenue (TTM): $246.71M as of Sep 30, 2020
EBITDA (TTM): -$584.72M as of Sep 30, 2020
Net annual income (TTM): -$597.70M as of Sep 30, 2020
Free cash flow (TTM): $612.85M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 395,710,105 as of Oct 20, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.